Breast Reconstruction

1
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
ARTIA Reconstructive Tissue MatrixPhase 31 trial
Active Trials
NCT06575192Recruiting783Est. Dec 2029
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
PERLE Sterile Smooth Opaque gel filled mammary implantsN/A1 trial
Active Trials
NCT06013514RecruitingEst. Sep 2038

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
2029
2030
2031
AbbVieARTIA Reconstructive Tissue Matrix
GC BiopharmaPERLE Sterile Smooth Opaque gel filled mammary implants

Clinical Trials (2)

Total enrollment: 783 patients across 2 trials

NCT06575192AbbVieARTIA Reconstructive Tissue Matrix

Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

Start: Nov 2024Est. completion: Dec 2029783 patients
Phase 3Recruiting
NCT06013514GC BiopharmaPERLE Sterile Smooth Opaque gel filled mammary implants

Post-market Prospective Clinical Study of Nagor Perle Mammary Implants

Start: Jun 2024Est. completion: Sep 2038
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 783 patients
2 companies competing in this space